
Sign up to save your podcasts
Or
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
4.5
238238 ratings
Jared Baeten is senior vice president in virology at Gilead Sciences. Jared's problem is this: In a world without a vaccine, how do you make a medicine that people will actually take to help prevent HIV?
There’s already a daily pill that reduces the risk of getting HIV, but a majority of people who are at high risk are unwilling or unable to take it.
So Jared and his colleagues are developing a new drug, lenacapivir, designed to be given as a shot once every six months.
Note: The views and opinions expressed in this episode are those of the guest and do not necessarily reflect the views or positions of any entities they represent.
Get early, ad-free access to episodes of What's Your Problem? by subscribing to Pushkin+ on Apple Podcasts or Pushkin.fm. Pushkin+ subscribers can access ad-free episodes, full audiobooks, exclusive binges, and bonus content for all Pushkin shows.
Subscribe on Apple: apple.co/pushkin
Subscribe on Pushkin: pushkin.com/plus
See omnystudio.com/listener for privacy information.
30,673 Listeners
32,118 Listeners
26,208 Listeners
59,002 Listeners
3,995 Listeners
4,097 Listeners
9,506 Listeners
9,536 Listeners
570 Listeners
14,304 Listeners
6,219 Listeners
5,089 Listeners
404 Listeners
73 Listeners
4,401 Listeners
2,098 Listeners
80 Listeners
391 Listeners
1,210 Listeners
266 Listeners
232 Listeners
4,315 Listeners
433 Listeners
147 Listeners
374 Listeners
332 Listeners
96 Listeners
1,613 Listeners
79 Listeners
249 Listeners
254 Listeners
65 Listeners